Abstract:Molecular imaging represents a powerful tool for the immediate diagnosis of early gastric cancers (EGCs). In this study, the human heavy-chain ferritin (HFn), which specifically recognizes tumor biomarker transferrin receptor-1 (TfR1), was labeled with fluorescent agents to enable real-time imaging by confocal laser endomicroscopy (CLE). : In vivo molecular imaging was performed in tumor-bearing mice from gastric cancer cell lines (BGC-823 and SGC-7901). Xenograft tumors were visualized in vivo first with a whole-body fluorescent imaging device and then by CLE using fluorescently labeled HFn-nanoprobe. Human EGC specimens were examined ex vivo by HFn-nanoprobe-based CLE. 1. Generation of the HFn-nanoprobe, and its specific conjunction with gastric cancer cell. We labeled the protein shell of HFn with a dye for ex vivo tumor-cell imaging, in vivo fluorescence molecular imaging, and ex vivo CLE imaging; and we bio-mimetically synthesized magneto-HFn nanoparticle (M-HFn) for tissue IHC staining. The protein shells of both dye-HFn and M-HFn nanoprobes presented a well-defined morphology and were monodisperse in size. Western blotting and FACS results showed the general expression of TfR1 in BGC-823 and SGC-7901 cells. After tumor cells incubated with FITC-HFn, FITC-HFn showed membranous and cytoplasmic staining patterns. 2. Macroscopic Fluorescence Detection of TfR1 in Mice. We used macroscopic whole-body fluorescence detection to examine tumor-targeting efficacy of HFn labeled with IRDye800CW-HFn in mice harboring BGC-823 and SGC-7901 cells. Both tumor models showed increased HFn-targeted imaging and specific fluorescence signals in the tumors 4 h after tail-vein injection of IRDye800CW-HFn and the signals were still detectable at 48 h after HFn administration. The results were verified by ex vivo bench-top fluorescence-microscopy imaging and M-HFn IHC staining of the tumor xenografts (Fig.1). 3. HFn Binding to Human EGC Tissues Ex Vivo. Twenty-two cases EGC specimens after endoscopic submucosal dissection were available. After the incubation with FITC-HFn on EGC specimens , all EGCs showed specific FITC-HFn signal (22/22), whereas noncancerous tissues exhibited no (21/22) or weak specific fluorescence (1/22) (P < 0.0001). There is negative correlation between degree of HFn fluorescence signal and degree of tumor differentiation. The results were verified by the IHC and bench-top fluorescence staining. Our results also showed FITC-HFn-CLE imaging provided high contrast between cancerous and noncancerous tissues (Fig.2). Our HFn-nanoprobe-based CLE method is a promising approach for detection of EGCs, and this TfR1-targeted molecular imaging increases the accuracy of EGC detection and enables the visualization of tumor margins and guiding endoscopic resection.Fig. 2FITC-HFn identifies EGC. In the white-light image, a tumor-lesion area (A) was confirmed through histological analysis; the area is shown as regions 1 and 2 (B). The FITC-HFn probe was topically applied onto the tumor specimen (C and D) for staining. Stereomicroscopy imaging revealed specific fluorescence was detected in the tumorous regions 1 and 2 after FITC-HFn staining (E and F). Under CLE, a specific signal was detected in cancerous lesions, and high-magnification imaging showed strong membranous and cytoplasmic staining (G and H). The results of the IHC and bench-top fluorescence staining of the targeted tissue were confirmed through H&E staining (I-K; red dashed line: diseased area).View Large Image Figure ViewerDownload Hi-res image Download (PPT)

Endoscopic Molecular Imaging of Early Gastric Cancer Using Fluorescently Labeled Human H-ferritin Nanoparticle.

Sa1221 ENDOSCOPIC MOLECULAR IMAGING OF EARLY GASTRIC CANCER USING HUMAN HEAVY-CHAIN FERRITIN NANOPROBE UNDER CONFOCAL LASER ENDOMICROSCOPY

Targeting Pancreatic Cancer with Magneto-Fluorescent Theranostic Gold Nanoshells.

Ultra-Small and Metabolizable Near-Infrared Au/Gd Nanoclusters for Targeted FL/MRI Imaging and Cancer Theranostics

Early Tumor Detection Afforded by in Vivo Imaging of Near-Infrared Ii Fluorescence

Folic acid-conjugated silica capped gold nanoclusters for targeted fluorescence/X-ray computed tomography imaging

The Dual-Response-Single-Amplification Fluorescent Nanomachine for Tumor Imaging and Gastric Cancer Diagnosis

Ferritin nanocages for early theranostics of tumors via inflammation-enhanced active targeting

Molecular Imaging of Ulex Europaeus Agglutinin in Colorectal Cancer Using Confocal Laser Endomicroscopy (With Video)

Excessive Expectations for Carcinoembryonic Antigen Targeted Fluorescent‐guided Surgery for Sentinel Lymph Node Detection in Colorectal, Pancreatic, and Gastric Cancer

Fibronectin-Targeting Dual-Modal MR/NIRF Imaging Contrast Agents for Diagnosis of Gastric Cancer and Peritoneal Metastasis

Targeted Biodegradable Near-Infrared Fluorescent Nanoparticles for Colorectal Cancer Imaging

Imaging Tiny Hepatic Tumor Xenografts Via Endoglin-Targeted Paramagnetic/Optical Nanoprobe

MR Molecular Imaging of HCC Employing a Regulated Ferritin Gene Carried by a Modified Polycation Vector.

Imaging hamster model of bile duct cancer in vivo using fluorescent L-glucose derivatives

A β-Galactosidase-Activated Fluorogenic Reporter for the Detection of Gastric Cancer In Vivo and in Urine

TfR1 binding with H-ferritin nanocarrier achieves prognostic diagnosis and enhances the therapeutic efficacy in clinical gastric cancer

Novel Near-Infrared Fluorescent Probe for Hepatocyte Growth Factor in Vivo Imaging in Surgical Navigation of Colorectal Cancer

In Vivo Fluorescence Imaging of Hepatocellular Carcinoma Using a Novel GPC3-specific Aptamer Probe

A Novel Approach for the Detection of Early Gastric Cancer: Fluorescence Spectroscopy of Gastric Juice

Superior Fluorescent Nanoemulsion Illuminates Hepatocellular Carcinoma for Surgical Navigation